The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer.
OBJECTIVE
To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model.


METHODS
In vitro and in vivo testing of immune therapy for SCC.


METHODS
Multiple SCC lines were infected by using advRSV-interleukin-12 (IL-12) and advCMV-interleukin-12/granulocyte macrophage colony-stimulating factor (IL-12/GM-CSF) and monitored for production of IL-12 and GM-CSF. Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival.


RESULTS
In vitro, all cell lines produced substantial levels of IL-12 and GM-CSF. In vivo, tumors treated with advCMV-IL-12/GM-CSF and Ig-4-1BBL showed a striking reduction in tumor volume (vs control P<0.0001) and improved median survival (38 days vs 19 days for control, P<0.0001).


CONCLUSIONS
Combination immune-based therapies effectively improve survival in mice bearing FOM SCC over single-modality therapy.
Adappa
Nithin D
ND
Department of Otolaryngology-Head and Neck Surgery, Mount Sinai School of Medicine, New York, New York 10003-4297, USA.
Sung
Chi-Kwang
CK
Choi
Bryan
B
Huang
Tian-Gui
TG
Genden
Eric M
EM
Shin
Edward J
EJ
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D004357:Drug Synergism; D004797:Enzyme-Linked Immunosorbent Assay; D015316:Genetic Therapy / Q000379:methods*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000096:biosynthesis; D007167:Immunotherapy / Q000379:methods; D018664:Interleukin-12 / Q000008:administration & dosage*; D051379:Mice; D009060:Mouth Floor; D009062:Mouth Neoplasms / Q000628:therapy*; D013997:Time Factors; D014407:Tumor Cells, Cultured
D018664:Interleukin-12; D016178:Granulocyte-Macrophage Colony-Stimulating Factor